The global intravenous (IV) ibuprofen market size was US$ 6.06 million in 2021. The global intravenous (IV) ibuprofen market size is forecast to reach US$ 16.48 million by 2030, growing at a compound annual growth rate (CAGR) of 13.5% during the forecast period from 2022 to 2030.

Ibuprofen belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs). Ibuprofen inhibits cyclooxygenase (COX) non-selectively, a process that leads to prostaglandin synthesis via arachidonic acid. Consequently, ibuprofen reduces the production of prostaglandins (PGs), which can lead to inflammation. The intravenous (IV) administration of ibuprofen alone or in combination with other analgesics helps to relieve mild to severe pain. Children and adults can both benefit from NSAIDs, such as ibuprofen. There is, however, a risk of ulcers and bleeding in the gastrointestinal tract (GIT) in geriatrics.

Factors Influencing Market Growth

• Increased prevalence of arthritis, cardiovascular diseases, and cancer are driving growth in the global intravenous (IV) ibuprofen market. Many types of cancer cause mild to severe pain, such as osteosarcoma (bone cancer), nerve cancer, and leukemia. 
• The quick analgesic action of ibuprofen and its bioavailability is forecast to drive their adoption, thus fueling the global market growth during the forecast period. 
• Food and Drug Administration (FDA) approved the use of intravenous (IV) ibuprofen injection in pediatric patients at definite doses. Increasing the use of ibuprofen injections in children increases the demand for intravenous (IV) ibuprofen injections. Therefore, a growing pediatric population drives the global market growth.
• The side effects associated with ibuprofen may slow down the overall market growth.

Impact Analysis of COVID-19

The COVID-19 epidemic has slowed the growth of the intravenous ibuprofen market, as most hospitals are closed due to COVID-19 lockdowns in numerous countries. A large number of clinics and hospitals worldwide were reorganizing to enhance hospital capacity and provide better healthcare, which increased bone cancer detection and treatment, contributing to market growth. In 2021, the American Cancer Society (ACS) reported approximately 3,910 new cases of bone cancer in the United States. In addition, ibuprofen's excellent bioavailability and quick analgesic effect are forecast to drive uptake during the projected period.

Regional Insights

North America held the majority of the market share in 2021 and is forecast to maintain its dominance throughout the forecast period. Due to the rising prevalence of bone cancer, the presence of key players in the development of intravenous (IV) ibuprofen medication, and the established infrastructure in the region. 

The Asia Pacific is forecast to experience lucrative growth during the forecast period. A high population and prevalence of arthritis are the main factors driving the market growth. Additionally, there is an increase in the number of hospitals, cancer prevalence, and pediatric population size, thus, driving the market growth in the region.

Leading Competitors

The leading prominent companies profiled in the global intravenous (IV) ibuprofen market are:

• AFT Pharmaceuticals
• Cumberland Pharmaceuticals Incorporated
• Dano Health Group
• Grifol, S.A.
• Harbin Gloria Pharmaceuticals Co., Limited
• Hyloris, Pharmaceuticals S.A.
• Pharma Bavaria International
• Recordati
• SG pharma
• XGEN
• Other Prominent Players

Scope of the Report

The global intravenous (IV) ibuprofen market segmentation focuses on Indication, Age Group, and Region.

Segmentation based on Indication

• Pain/Inflammatory
• Fever

Segmentation based on Age Group

• Pediatrics
• Adults

Segmentation based on Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America